Story to be published July 11, 2008.
Dr. Behlke, his team and collaborators are working on improving the delivery of Dicer-substrate siRNAs (DsiRNAs) in vitro and in vivo.
His work has helped establish siRNA technology as a viable tool for drug development.
Please see the article titled RNAi Researchers Galvanized by Advances: Technology’s Viability in Drug Development Is Finally Established by Elizabeth Lipp.
It appeared in the June 1, 2008 issue of Genetic Engineering & biotechnology News.
Here’s a notable quote from Dr. Behlke:
Long dsRNAs have been employed for many years as a means to modulate gene expression in plants, yeast, and C. elegans. Similar attempts in higher organisms failed due to interferon activation, however we now know that short RNA duplexes can be safely used in mammalian systems both in vitro and in vivo.
The technology has rapidly matured, thanks in large part to all that was learned over the past 20 years using antisense oligonucleotides. RNAi is now routinely employed in vivo as an experimental tool and numerous groups are vigorously pursing the use of RNAi compounds as therapeutics. Several siRNA drugs are already in clinical trials and more are in preclinical development.
My first “News Behind the News” story posted to this Neuromics blog will feature Dr. Mark Behlke, CSO, Integrated DNA Technologies.